GSK, iTeos collaborate on cancer drug development in up to $2bn deal
GSK and iTeos Therapeutics have joined forces to jointly develop and co-commercialise EOS-448, an investigational anti-TIGIT monoclonal antibody for cancer treatment. EOS-448 is a monoclonal antibody that binds